Research programme: cancer immunotherapeutics - PsiOxus Therapeutics

Drug Profile

Research programme: cancer immunotherapeutics - PsiOxus Therapeutics

Alternative Names: AbEnAds; anti-human VEGF armed EnAd; anti-PDL1 AbEnAds; NG 345; NG 347; NG 348; NG 350a; NG 600; NG-600 series

Latest Information Update: 18 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PsiOxus Therapeutics
  • Class Antibodies; Antineoplastics; Oncolytic viruses
  • Mechanism of Action CD274 antigen inhibitors; Cytotoxic T-lymphocyte antigen 4 inhibitors; Immunomodulators; Immunostimulants; Vascular endothelial growth factors modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 18 Jul 2017 PsiOxus Therapeutics plans a phase I trial for NG 600 for Cancer (PsiOxus pipeline, January 2017).
  • 20 Dec 2016 NG 348 licensed to Bristol-Myers Squibb worldwide which is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act
  • 14 Apr 2016 PsiOxus Therapeutics and Parker Institute for Cancer enter into a memorandum of understaing for an anticipated collaboration using the Tumor-Specific Immuno-Gene Therapy (T-SIGn) platform developed by PsiOxus Therapeutics for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top